Shiyao Group (01093.HK): The Phase III clinical study of the combination of Enlotuzumab and SAW for the treatment of driver gene-negative non-small cell lung cancer has officially started in China.

According to the Zhitong Financial APP, Shiyao Group (01093.HK) issued an announcement that the Phase III clinical study (study protocol number: SYS6010-022 (SYNSTAR-04)) of the combination of SYS6010 jointly developed by the Group with Enlov and Suvadantuzumab for the treatment of driver gene-negative non-small cell lung cancer ("NSCLC") has officially started in China, with plans to complete the enrollment of the first subject by July 2026.